openPR Logo
Press release

Adult-onset Growth Hormone Deficiency Market to Witness Growth by 2032 | Novo Nordisk, Ascendis Pharma, expected to boost the market

12-08-2023 12:29 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Adult-onset Growth Hormone Deficiency Market

Adult-onset Growth Hormone Deficiency Market

DelveInsight's "Adult-onset Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Adult-onset Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Adult-onset Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Adult-onset Growth Hormone Deficiency market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Adult-onset Growth Hormone Deficiency market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Adult-onset Growth Hormone Deficiency treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Adult-onset Growth Hormone Deficiency market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adult-onset Growth Hormone Deficiency: An Overview

Adult-onset growth hormone deficiency (AGHD) is a condition characterized by a decrease in the production or secretion of growth hormone (GH) in adults. Unlike childhood growth hormone deficiency, which can lead to stunted growth if not treated during development, adult-onset GH deficiency affects individuals after they have achieved their full height.
Causes of adult-onset growth hormone deficiency can include:
Pituitary Tumor or Lesions: Tumors or other conditions affecting the pituitary gland can disrupt the production of growth hormone.
Head Trauma: Injuries or trauma to the head can damage the pituitary gland, affecting hormone production.
Brain Surgery or Radiation Therapy: Treatment for pituitary tumors or other brain-related conditions can inadvertently damage the pituitary gland, leading to decreased GH production.
Idiopathic Causes: In some cases, the cause of adult-onset GH deficiency may not be identifiable, referred to as idiopathic GH deficiency.
Symptoms of adult-onset growth hormone deficiency can be subtle and nonspecific, often overlapping with signs of normal aging. These may include:
Decreased energy levels and stamina
Reduced muscle mass and strength
Increased body fat, especially around the waist
Impaired cognitive function, memory, and concentration
Decreased bone density, potentially leading to osteoporosis
Changes in lipid metabolism, such as increased cholesterol levels
Impaired cardiac function
Diagnosis of AGHD involves clinical evaluation, blood tests to measure growth hormone levels, insulin-like growth factor 1 (IGF-1) levels, and sometimes stimulation tests to assess the pituitary gland's response to certain stimuli.
Treatment for adult-onset GH deficiency typically involves hormone replacement therapy (HRT) using synthetic growth hormone injections. The goal of treatment is to alleviate symptoms, improve body composition, increase energy levels, enhance quality of life, and potentially reduce the risk of associated complications like osteoporosis.
HRT requires regular monitoring by healthcare professionals to adjust the dosage and assess treatment efficacy and safety. As with any medical intervention, potential risks and benefits should be discussed with a healthcare provider to determine the most suitable treatment plan for each individual.

Learn more about Adult-onset Growth Hormone Deficiency, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adult-onset Growth Hormone Deficiency Market

The Adult-onset Growth Hormone Deficiency market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Adult-onset Growth Hormone Deficiency market trends by analyzing the impact of current Adult-onset Growth Hormone Deficiency therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Adult-onset Growth Hormone Deficiency market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Adult-onset Growth Hormone Deficiency market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Adult-onset Growth Hormone Deficiency market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adult-onset Growth Hormone Deficiency Epidemiology

The Adult-onset Growth Hormone Deficiency epidemiology section provides insights into the historical and current Adult-onset Growth Hormone Deficiency patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Adult-onset Growth Hormone Deficiency market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Adult-onset Growth Hormone Deficiency Epidemiology at: https://www.delveinsight.com/report-store/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adult-onset Growth Hormone Deficiency Drugs Uptake

This section focuses on the uptake rate of the potential Adult-onset Growth Hormone Deficiency drugs recently launched in the Adult-onset Growth Hormone Deficiency market or expected to be launched in 2019-2032. The analysis covers the Adult-onset Growth Hormone Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Adult-onset Growth Hormone Deficiency Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Adult-onset Growth Hormone Deficiency market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adult-onset Growth Hormone Deficiency Pipeline Development Activities

The Adult-onset Growth Hormone Deficiency report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Adult-onset Growth Hormone Deficiency key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Adult-onset Growth Hormone Deficiency pipeline development activities at: https://www.delveinsight.com/sample-request/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adult-onset Growth Hormone Deficiency Therapeutics Assessment

Major key companies are working proactively in the Adult-onset Growth Hormone Deficiency Therapeutics market to develop novel therapies which will drive the Adult-onset Growth Hormone Deficiency treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adult-onset Growth Hormone Deficiency Report Key Insights

1. Adult-onset Growth Hormone Deficiency Patient Population
2. Adult-onset Growth Hormone Deficiency Market Size and Trends
3. Key Cross Competition in the Adult-onset Growth Hormone Deficiency Market
4. Adult-onset Growth Hormone Deficiency Market Dynamics (Key Drivers and Barriers)
5. Adult-onset Growth Hormone Deficiency Market Opportunities
6. Adult-onset Growth Hormone Deficiency Therapeutic Approaches
7. Adult-onset Growth Hormone Deficiency Pipeline Analysis
8. Adult-onset Growth Hormone Deficiency Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Adult-onset Growth Hormone Deficiency Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Adult-onset Growth Hormone Deficiency Competitive Intelligence Analysis
4. Adult-onset Growth Hormone Deficiency Market Overview at a Glance
5. Adult-onset Growth Hormone Deficiency Disease Background and Overview
6. Adult-onset Growth Hormone Deficiency Patient Journey
7. Adult-onset Growth Hormone Deficiency Epidemiology and Patient Population
8. Adult-onset Growth Hormone Deficiency Treatment Algorithm, Current Treatment, and Medical Practices
9. Adult-onset Growth Hormone Deficiency Unmet Needs
10. Key Endpoints of Adult-onset Growth Hormone Deficiency Treatment
11. Adult-onset Growth Hormone Deficiency Marketed Products
12. Adult-onset Growth Hormone Deficiency Emerging Therapies
13. Adult-onset Growth Hormone Deficiency Seven Major Market Analysis
14. Attribute Analysis
15. Adult-onset Growth Hormone Deficiency Market Outlook (7 major markets)
16. Adult-onset Growth Hormone Deficiency Access and Reimbursement Overview
17. KOL Views on the Adult-onset Growth Hormone Deficiency Market
18. Adult-onset Growth Hormone Deficiency Market Drivers
19. Adult-onset Growth Hormone Deficiency Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Adult-onset Growth Hormone Deficiency Market report here: https://www.delveinsight.com/report-store/adult-onset-growth-hormone-deficiency-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adult-onset Growth Hormone Deficiency Market to Witness Growth by 2032 | Novo Nordisk, Ascendis Pharma, expected to boost the market here

News-ID: 3320998 • Views:

More Releases from DelveInsight Business Research LLP

Tirzepatide Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Eli Lilly and Company
Tirzepatide Market Size and Share Across 7MM and Competitive Landscape by DelveI …
DelveInsight has released a comprehensive report titled "Tirzepatide Market Forecast" offering a thorough examination and predictive insights into the Tirzepatide market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of Tirzepatide in the therapeutics landscape for Obesity across the 7MM, spanning
SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Novo Nordisk
SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape …
DelveInsight has released a comprehensive report titled "SAXENDA (Liraglutide) Market Forecast" offering a thorough examination and predictive insights into the SAXENDA (Liraglutide) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of SAXENDA (Liraglutide) in the therapeutics landscape for Obesity across
High-Grade Glioma Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BioMimetix, Oblato, PTC Therapeutics, Lee's Pharmaceutical, Nuvation Bio, Laminar Pharma, Basilea Pharma
High-Grade Glioma Pipeline Analysis Covering Clinical Trials, Emerging Therapies …
As per DelveInsight's assessment, globally, about 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the High-Grade Glioma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "High-Grade Glioma Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis
Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Capricor Therapeutics (CAP-1002), Santhera, Sarepta, Italfarmaco, FibroGen, Pfizer, Daiichi Sankyo
Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Em …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Duchenne Muscular Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Duchenne Muscular Dystrophy Pipeline Insight"

All 5 Releases


More Releases for Hormone

Hormone Replacement Therapy Market Report- Segment by Application Menopause, Hyp …
The Hormone Replacement Therapy Market research report presents an intensive and coordinated exploration of the current circumstance, market key elements, Hormone Replacement Therapy Market methodologies, and central participants' development in the business. The investigation helps controllers and corporate leaders in developing cost-effective decisions. Hormone Replacement Therapy Market provides an evenhanded and extensive assessment of existing examples, factors, obstacles, limits, headway, possibilities/quick development areas that will help partners create business plans
Competitive and Opportunities Analysis of Hormone Replacement Therapy Market of …
The global hormone replacement therapy market accounted for US$ 7.16 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to register a CAGR of 7.50%. Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause.These symptoms can include hot flashes, vaginal atrophy, accelerated skin aging,
Growth Hormone Deficiency (GHD) Treatment Market
Growth Hormone Deficiency (GHD) Treatment Market: Overview The growth hormone deficiency (GHD) treatment market has made some notable strides on the back of the growing role of GH replacement therapy in managing GHD in adults. Advances in understanding clinical syndrome of GHD and understanding of diagnosis are key trends boosting the GHD treatment market. Clinical practices pertaining to pharmacological management of the syndrome in the GHD treatment market have made remarkable
Luteinizing Hormone-releasing Hormone Analogs Drugs Market Analysis by Manufactu …
" Los Angeles, United States – – QY Research offers an overarching research and analysis-based study on the global Luteinizing Hormone-releasing Hormone Analogs Drugs market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global Luteinizing Hormone-releasing Hormone Analogs Drugs market. The researchers and analysts who have prepared the
Luteinizing Hormone-releasing Hormone Analogs Market Size, Analysis, Research, S …
" Los Angeles, United States – – QY Research offers an overarching research and analysis-based study on the global Luteinizing Hormone-releasing Hormone Analogs market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global Luteinizing Hormone-releasing Hormone Analogs market. The researchers and analysts who have prepared the report used
Peptide Hormone Market- Key Development by 2026
Worldwide Peptide Hormone Market report of 2019 provides a detailed market overview as well as industry analysis for / of companies, manufacturers and distributors covering data on gross margin, cost structure, consumption value, sale price and more. The recent research report on the global Peptide Hormone market presents the latest industry data and future trends, allowing you to recognize the products and end users driving Revenue growth and profitability of the